Piperacillin/tazobactam

ApprovedSmall molecule

Pfizer

Piperacillin/tazobactam is one of 262 small molecule programs targeting Neutropenia. It is currently in Approved.

Indications

Total Trials

Active Trials

261

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Bacterial PneumoniaActive, not recruiting

AppendicitisActive, not recruiting

LymphomaActive, not recruiting

PneumoniaActive, not recruiting

SepsisActive, not recruiting

Septic ShockActive, not recruiting

COVID-19Active, not recruiting

Ventilator-Associated PneumoniaActive, not recruiting

Diabetic FootActive, not recruiting

NeutropeniaApproved

Active, not recruiting

Bacterial PneumoniaPhase 3

Active, not recruiting

AppendicitisApproved

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

SepsisApproved

Active, not recruiting

Septic ShockApproved

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Ventilator-Associated PneumoniaPhase 3

Active, not recruiting

Diabetic FootApproved

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Piperacillin/tazobactam

Pfizer

Approved

1 2

Bnt162b2

BioNTech

Preclinical

29 3

Aldactone

Pfizer

Preclinical

1 4

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Glucocorticoid

AbbVie

Preclinical

1 7

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 8

Olokizumab

UCB

Preclinical

1 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ANot yet recruiting

Pneumonia

NCT06977347

Q2 2027

Post-ApprovalRecruiting

Bloodstream Infection

NCT03671967

Q1 2029

Post-ApprovalRecruiting

Sepsis

NCT06184659

Clinical

Trials by Indication[1]

Antibiotics2 trials

Antibiotics Continuous Infusion at Home

Unknown status·OOspedale San Carlo Borromeo·Phase 1·NCT04816968·50 enrolled

Computer-based Dosage Calculation for Antibiotics

Withdrawn·UUniversity Hospital Tuebingen··NCT03036826

Sepsis2 trials

Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.

Unknown status·SShandong University·Phase 4·NCT05981079·332 enrolled

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

Recruiting·SScandinavian Critical Care Trials Group·Phase 4·NCT06184659·5,800 enrolled

Pneumonia2 trials

Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea

Not yet recruiting·CCHOSEOK YOON·N/A·NCT06977347·100 enrolled

Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia

Completed· Sanofi logo

Sanofi·Phase 3·NCT00253955·460 enrolled

Antibiotic Therapy2 trials

Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Unknown status·AAzienda Sanitaria-Universitaria Integrata di Udine··NCT04132115·104 enrolled

Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection

Completed·CCanadian Critical Care Trials Group·Phase 2·NCT00438269·80 enrolled

Appendicitis2 trials

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

Completed·NNYU Langone Health·Phase 4·NCT02991937·39 enrolled

Assessing the Longitudinal Outcomes of Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA): a Randomized Controlled Trial

Completed·MMcMaster Children's Hospital·Phase 2·NCT05943223·16 enrolled

23 more indications

Infection1 trial

Antimicrobial PK in Infants With Suspected or Confirmed Infection

Completed·—··NCT00491426·450 enrolled

Neutropenia1 trial

Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 4·NCT02463747·110 enrolled

Open Fracture1 trial

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

Terminated·MMercy Health Ohio·Phase 4·NCT03560232·17 enrolled

Bacteremia1 trial

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

Recruiting·IInstituto Nacional de Cancerologia de Mexico·N/A·NCT06422533·226 enrolled

Cancer1 trial

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Terminated·FForest Laboratories·Phase 2·NCT02732327·2 enrolled

Infections1 trial

Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

Completed· Pfizer logo

Pfizer··NCT00195286·180 enrolled

Intra-abdominal Infection1 trial

Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection

Completed· Pfizer logo

Pfizer·Phase 4·NCT00044928·262 enrolled

Renal Replacement Therapy1 trial

Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy

Completed·UUniversity Hospital, Toulouse·Phase 4·NCT00703144·10 enrolled

Diabetic Foot1 trial

Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

Completed· Pfizer logo

Pfizer·Phase 4·NCT00044746·314 enrolled

Bacterial Pneumonia1 trial

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Withdrawn·MMelinta Therapeutics, Inc.·Phase 3·NCT03006679

Intravenous1 trial

A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03441529·18 enrolled

Urinary Tract Infection1 trial

Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

Completed·AAllecra·Phase 3·NCT03687255·1,043 enrolled

Phase 11 trial

Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

Completed·SSpero Therapeutics·Phase 1·NCT03376529·27 enrolled

Critically Ill Patients1 trial

Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients

Completed·RRadboud University Medical Center··NCT03738683·40 enrolled

Concentration1 trial

Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion

Terminated·UUniversity Hospital Tuebingen··NCT00435305·40 enrolled

Chronic Pulmonary Disease1 trial

Targeted AntiBiotics for Chronic Pulmonary Diseases

Terminated·CChronic Obstructive Pulmonary Disease Trial Network, Denmark·Phase 4·NCT03262142·51 enrolled

Antibiotic Prophylaxis1 trial

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

Terminated·—·Phase 2·NCT05753735·3 enrolled

Septic Shock1 trial

Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock

Terminated·FFraser Health·Phase 4·NCT00816790·20 enrolled

Bloodstream Infection1 trial

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Recruiting·RRambam Health Care Campus·Phase 4·NCT03671967·1,084 enrolled

Ventilator-Associated Pneumonia1 trial

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01853982·4 enrolled

Surgical Site Infections1 trial

Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

Terminated· Menarini logo

Menarini·Phase 3·NCT04042077·268 enrolled

COVID-191 trial

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19

Suspended·FFundacion GenesisCare·N/A·NCT04394182·15 enrolled

Lymphoma1 trial

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

Completed· Pfizer logo

Pfizer·Phase 3·NCT00044759

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Piperacillin/tazobactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Piperacillin/tazobactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Piperacillin/tazobactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Piperacillin/tazobactam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2029

Trials by Indication[1]

Antibiotics2 trials

Sepsis2 trials

Pneumonia2 trials

Antibiotic Therapy2 trials

Appendicitis2 trials

Infection1 trial

Neutropenia1 trial

Open Fracture1 trial

Bacteremia1 trial

Cancer1 trial

Infections1 trial

Intra-abdominal Infection1 trial

Renal Replacement Therapy1 trial

Diabetic Foot1 trial

Bacterial Pneumonia1 trial

Intravenous1 trial

Urinary Tract Infection1 trial

Phase 11 trial

Critically Ill Patients1 trial

Concentration1 trial

Chronic Pulmonary Disease1 trial

Antibiotic Prophylaxis1 trial

Septic Shock1 trial

Bloodstream Infection1 trial

Ventilator-Associated Pneumonia1 trial

Surgical Site Infections1 trial

COVID-191 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News